(Q38098466)

28 August 2017

title

Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents (English)

1 reference

28 August 2017

1 reference

Emily Yiping Gan

1

1 reference

28 August 2017

Wei-Sheng Chong

series ordinal

2

1 reference

28 August 2017

Hong Liang Tey

series ordinal

3

1 reference

28 August 2017

language of work or name

1 reference

1 August 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

27

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

359-373

1 reference

https://scigraph.springernature.com/pub.10.1007/s40259-013-0025-6

28 August 2017

exact match

0 references

cites work

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Psoriasis causes as much disability as other major medical diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The IL-23/Th17 axis in the immunopathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Role of IL-17 in psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Evaluation and management of psoriatic arthritis: the role of biologic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Genetic epidemiology of psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Treatment recommendations for psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Current systemic therapies for psoriasis: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Folate supplementation during methotrexate therapy for patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Combination systemic therapies in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Lymphoma risk in psoriasis: results of the PUVA follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Methotrexate and histologic hepatic abnormalities: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Clinical applications of transient elastography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Performance of transient elastography for the staging of liver fibrosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Leflunomide: mode of action in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Treatment of severe psoriasis and psoriatic arthritis with leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Leflunomide: a review of its use in active rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Etanercept combined with methotrexate for high-need psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Review and expert opinion on prevention and treatment of infliximab-related infusion reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

New biologics for psoriasis and psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

The IL-17 cytokine family.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Psoriasis: rationale for targeting interleukin-17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Keynote review: phosphodiesterase-4 as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phospho

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Novel systemic drugs under investigation for the treatment of psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0025-6

Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling

21 January 2018

1 reference

31 May 2024

https://opencitations.net/index/api/v1/citations/10.1172/JCI40202

Identifiers

DOI

10.1007/S40259-013-0025-6

1 reference

28 August 2017

1 reference